/
DES-PCI was inferior  to CABG for clinical outcomes at 5 years following revascularization DES-PCI was inferior  to CABG for clinical outcomes at 5 years following revascularization

DES-PCI was inferior to CABG for clinical outcomes at 5 years following revascularization - PowerPoint Presentation

arya
arya . @arya
Follow
27 views
Uploaded On 2024-02-02

DES-PCI was inferior to CABG for clinical outcomes at 5 years following revascularization - PPT Presentation

lesions The hazard was highest with CABG in the first 30 days with better outcomes with PCI between 30 days and 5 years outcomes were inferior with PCI compared with CABG CABG n 592 ID: 1044073

cabg pci outcomes des pci cabg des outcomes years revasc days repeat 592 main stroke left unprotected inferior endpoint

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "DES-PCI was inferior to CABG for clinic..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

1. DES-PCI was inferior to CABG for clinical outcomes at 5 years following revascularization of unprotected left main lesionsThe hazard was highest with CABG in the first 30 days with better outcomes with PCI; between 30 days and 5 years, outcomes were inferior with PCI compared with CABGCABG(n = 592)DES-PCI(n = 592)NOBLEPrimary endpoint: Death/MI/stroke/repeat revasc: PCI vs. CABG: 28.9% vs. 19.1%, p = 0.0066Death: 11.6% vs. 9.5%, p = 0.77; MI: 6.9% vs. 1.9%, p = 0.004; stroke: 4.9% vs. 1.7%, p = 0.07; repeat revasc: 16.2% vs. 10.4%, p = 0.03; de novo lesion revasc: 6% vs. 3%, p = 0.018Stent thrombosis/graft occlusion: 3% vs. 4%, p = 0.22Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They were followed for 5 years.ResultsConclusionsMäkikallio T, et al. Lancet 2016;388:2743-52 Primary endpoint(p = 0.0066)%